ME02608B - Kombinacija, komplet i postupak snižavanja intraokularnog pritiska - Google Patents
Kombinacija, komplet i postupak snižavanja intraokularnog pritiskaInfo
- Publication number
- ME02608B ME02608B MEP-2017-11A MEP1117A ME02608B ME 02608 B ME02608 B ME 02608B ME P1117 A MEP1117 A ME P1117A ME 02608 B ME02608 B ME 02608B
- Authority
- ME
- Montenegro
- Prior art keywords
- combination
- compound
- eye
- subject
- use according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 230000004406 elevated intraocular pressure Effects 0.000 claims 4
- 229960001160 latanoprost Drugs 0.000 claims 3
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims 3
- AQLVRTWKJDTWQQ-SDBHATRESA-N [(2r,3s,4r,5r)-5-[6-(cyclopentylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl nitrate Chemical compound O[C@@H]1[C@H](O)[C@@H](CO[N+]([O-])=O)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 AQLVRTWKJDTWQQ-SDBHATRESA-N 0.000 claims 2
- 229960002470 bimatoprost Drugs 0.000 claims 2
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229960002368 travoprost Drugs 0.000 claims 2
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims 2
- 229960004317 unoprostone Drugs 0.000 claims 2
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 claims 2
- 206010030043 Ocular hypertension Diseases 0.000 claims 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 201000006366 primary open angle glaucoma Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Prostheses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29380610P | 2010-01-11 | 2010-01-11 | |
| PCT/US2011/020808 WO2011085361A1 (en) | 2010-01-11 | 2011-01-11 | Combination, kit and method of reducing intraocular pressure |
| EP11732309.7A EP2523669B1 (en) | 2010-01-11 | 2011-01-11 | Combination, kit and method of reducing intraocular pressure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02608B true ME02608B (me) | 2017-06-20 |
Family
ID=44258984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-11A ME02608B (me) | 2010-01-11 | 2011-01-11 | Kombinacija, komplet i postupak snižavanja intraokularnog pritiska |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8877732B2 (forum.php) |
| EP (1) | EP2523669B1 (forum.php) |
| JP (2) | JP2013516495A (forum.php) |
| KR (1) | KR20120115344A (forum.php) |
| CN (1) | CN102711771B (forum.php) |
| AU (1) | AU2011203897B2 (forum.php) |
| BR (1) | BR112012017106A2 (forum.php) |
| CA (1) | CA2784908A1 (forum.php) |
| CL (1) | CL2012001912A1 (forum.php) |
| CO (1) | CO6571924A2 (forum.php) |
| CY (1) | CY1118510T1 (forum.php) |
| DK (1) | DK2523669T3 (forum.php) |
| EA (1) | EA025415B1 (forum.php) |
| ES (1) | ES2613698T3 (forum.php) |
| HR (1) | HRP20170007T1 (forum.php) |
| HU (1) | HUE030566T2 (forum.php) |
| IL (1) | IL220604A (forum.php) |
| IN (1) | IN2012DN06592A (forum.php) |
| LT (1) | LT2523669T (forum.php) |
| ME (1) | ME02608B (forum.php) |
| MX (1) | MX2012007661A (forum.php) |
| PH (1) | PH12012501320A1 (forum.php) |
| PL (1) | PL2523669T3 (forum.php) |
| PT (1) | PT2523669T (forum.php) |
| RS (1) | RS55615B1 (forum.php) |
| SG (2) | SG182285A1 (forum.php) |
| SI (1) | SI2523669T1 (forum.php) |
| SM (2) | SMT201700017T1 (forum.php) |
| WO (1) | WO2011085361A1 (forum.php) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ596428A (en) * | 2009-05-01 | 2014-03-28 | Inotek Pharmaceuticals Corp | Method of reducing intraocular pressure in humans |
| IN2012DN06592A (forum.php) | 2010-01-11 | 2015-10-23 | Inotek Pharmaceuticals Corp | |
| SG184221A1 (en) | 2010-03-26 | 2012-10-30 | Inotek Pharmaceuticals Corp | Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof |
| SI2807178T1 (sl) * | 2012-01-26 | 2017-09-29 | Inotek Pharmaceuticals Corporation | Anhidridni polimorf (2R,3S,4R,5R)-5-(6-(ciklofentilamino)-9H-purin-9-il)-3,4-dihidroksite- trahidrofuran-2-il))metil nitrat in postopki njegove priprave |
| KR20150139501A (ko) * | 2013-03-15 | 2015-12-11 | 이노텍 파마슈티컬스 코포레이션 | 안과용 제형 |
| CN105188713A (zh) * | 2013-03-15 | 2015-12-23 | 伊诺泰克制药公司 | 提供眼部神经保护的方法 |
| RU2712163C2 (ru) | 2014-10-24 | 2020-01-24 | Оно Фармасьютикал Ко., Лтд. | Активатор kcnq2-5 каналов |
| US20160158267A1 (en) * | 2014-12-03 | 2016-06-09 | Inotek Pharmaceuticals Corporation | Methods of preventing, reducing or treating macular degeneration |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4935635B1 (forum.php) | 1970-12-28 | 1974-09-25 | ||
| CH563405A5 (forum.php) | 1971-09-10 | 1975-06-30 | Duschinsky Robert Dr Schweiz I | |
| DE2226295A1 (de) | 1972-05-30 | 1973-12-20 | Henning Berlin Gmbh | Salpetersaeureester von purinnucleosiden und verfahren zur herstellung derselben |
| DE2342479A1 (de) | 1973-08-23 | 1975-03-13 | Merck Patent Gmbh | Ribonucleosid-5'-nitrate und verfahren zu ihrer herstellung |
| GB2001976B (en) | 1977-08-03 | 1982-03-10 | Yamasa Shoyu Kk | S-adenosyl-l-methionine compositions and production thereof |
| US4849311A (en) | 1986-09-24 | 1989-07-18 | Toa Nenryo Kogyo Kabushiki Kaisha | Immobilized electrolyte membrane |
| US4968697A (en) | 1987-02-04 | 1990-11-06 | Ciba-Geigy Corporation | 2-substituted adenosine 5'-carboxamides as antihypertensive agents |
| US5219840A (en) | 1987-04-06 | 1993-06-15 | Sandoz Ltd. | Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives |
| US5221763A (en) * | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| US5591887A (en) * | 1987-04-30 | 1997-01-07 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| US6187813B1 (en) * | 1990-04-10 | 2001-02-13 | Pharmacia & Upjohn Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| DE03014533T1 (de) * | 1988-09-06 | 2004-07-15 | Pharmacia Ab | Prostaglandinderivative zur Behandlung von Glaukom oder okuläre Hypertension |
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5140015A (en) | 1990-02-20 | 1992-08-18 | Whitby Research, Inc. | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents |
| US5280015A (en) | 1990-09-05 | 1994-01-18 | The United States Of America As Represented By The Department Of Health And Human Services | 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides |
| JP3020580B2 (ja) | 1990-09-28 | 2000-03-15 | 株式会社日立製作所 | マイクロ波プラズマ処理装置 |
| US5206222A (en) | 1991-05-22 | 1993-04-27 | Vanderbilt University | Methods for the reduction of myocardial reperfusion injury |
| HU212570B (en) * | 1991-06-24 | 1996-08-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester |
| US5407793A (en) | 1991-10-18 | 1995-04-18 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | An aqueous heart preservation and cardioplegia solution |
| US5278150A (en) | 1992-04-24 | 1994-01-11 | Whitby Research, Inc. | 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions |
| DK62692D0 (forum.php) | 1992-05-14 | 1992-05-14 | Novo Nordisk As | |
| AU4772493A (en) | 1992-07-15 | 1994-02-14 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Sulfo-derivatives of adenosine |
| US5972991A (en) * | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5338430A (en) | 1992-12-23 | 1994-08-16 | Minnesota Mining And Manufacturing Company | Nanostructured electrode membranes |
| US5443836A (en) | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
| EP0708781B1 (en) | 1993-07-13 | 2001-10-04 | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services | A 3 adenosine receptor agonists |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| WO1995011681A1 (en) | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
| US5620676A (en) | 1994-03-08 | 1997-04-15 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically active ATP analogs |
| EP0704215A3 (en) | 1994-06-02 | 1998-04-01 | Takeda Chemical Industries, Ltd. | Inhibitor of vascular permeability enhancer |
| GB9414193D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
| US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
| CN1164122A (zh) | 1996-03-01 | 1997-11-05 | 株式会社日立制作所 | 等离子处理机及其处理方法 |
| AU2022497A (en) | 1996-03-13 | 1997-10-01 | Novo Nordisk A/S | A method of treating disorders related to cytokines in mammals |
| WO1997033879A1 (en) | 1996-03-15 | 1997-09-18 | Merck & Co., Inc. | Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor |
| US5789416B1 (en) | 1996-08-27 | 1999-10-05 | Cv Therapeutics Inc | N6 mono heterocyclic substituted adenosine derivatives |
| TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| CA2289731A1 (en) | 1997-05-09 | 1998-11-12 | The United States Of America, Represented By The Secretary, Department O F Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| JP2001519386A (ja) | 1997-10-15 | 2001-10-23 | トーマス・ジェファーソン・ユニバーシティ | 哺乳動物における血管収縮または血管痙攣を予防または緩和するための一酸化窒素供与体組成物、方法、装置およびキット |
| WO1999020284A1 (en) | 1997-10-23 | 1999-04-29 | Trustees Of The University Of Pennsylvania | Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents |
| GB9723590D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| GB9723566D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| FR2775901B1 (fr) * | 1998-03-13 | 2000-07-21 | Logeais Labor Jacques | Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments |
| GB9813535D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| US6528516B1 (en) | 1998-07-16 | 2003-03-04 | Trustees Of The University Of Pennsylvania, The Center For Technology Transfer | Methods for reducing intraocular pressure using A3 adenosine receptor antagonists |
| EP1121372B1 (en) | 1998-10-16 | 2006-06-28 | Pfizer Limited | Adenine derivatives |
| IL127947A0 (en) | 1999-01-07 | 1999-11-30 | Can Fite Technologies Ltd | Pharmaceutical use of adenosine agonists |
| US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US6214807B1 (en) | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
| US6180615B1 (en) | 1999-06-22 | 2001-01-30 | Cv Therapeutics, Inc. | Propargyl phenyl ether A2A receptor agonists |
| US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| EP1194441B1 (en) | 1999-06-22 | 2003-10-22 | Cv Therapeutics, Inc. | A2a receptor agonists |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| GB9924361D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
| US6368573B1 (en) | 1999-11-15 | 2002-04-09 | King Pharmaceuticals Research And Development, Inc. | Diagnostic uses of 2-substituted adenosine carboxamides |
| US6258793B1 (en) | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
| GB9930071D0 (en) | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
| GB0003960D0 (en) | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
| US20010051612A1 (en) | 2000-02-23 | 2001-12-13 | Gloria Cristalli | 2-Thioether A2A receptor agonists |
| US20030010454A1 (en) | 2000-03-27 | 2003-01-16 | Bailey Andrew D. | Method and apparatus for varying a magnetic field to control a volume of a plasma |
| US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
| US6753322B2 (en) | 2000-06-06 | 2004-06-22 | Pfizer Inc | 2-aminocarbonyl-9H-purine derivatives |
| US6921753B2 (en) | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
| EP1307191A2 (en) | 2000-07-28 | 2003-05-07 | Inspire Pharmaceuticals, Inc. | Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure |
| WO2002055085A2 (en) | 2001-01-16 | 2002-07-18 | Can-Fite Biopharma Ltd. | Use of an adenosine a3 receptor agonist for inhibition of viral replication |
| GB2372742A (en) | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| US20040204481A1 (en) | 2001-04-12 | 2004-10-14 | Pnina Fishman | Activation of natural killer cells by adenosine A3 receptor agonists |
| US20030013675A1 (en) | 2001-05-25 | 2003-01-16 | Boehringer Ingelheim Pharma Kg | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases |
| US7713946B2 (en) | 2002-07-11 | 2010-05-11 | Cv Therapeutics, Inc. | Partial and full agonists A1 adenosine receptors |
| CA2456806C (en) | 2001-08-08 | 2011-10-18 | Brown University Research Foundation | Methods for micronization of hydrophobic drugs |
| WO2003029264A2 (en) | 2001-10-01 | 2003-04-10 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
| DE60325572D1 (de) | 2002-04-18 | 2009-02-12 | Cv Therapeutics Inc | Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker |
| MXPA04009471A (es) | 2002-04-30 | 2005-01-25 | Alcon Inc | Agentes que regulan, inhiben o modulan la actividad y/o expresion de factor de crecimiento de tejido de conexion (ctgf) como un medio unico para ambos reducir la presion intraocular y tratar retinopatias glaucomatosas/neuropatias opticas. |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| GB2436255B (en) | 2002-12-23 | 2007-11-28 | Global Cardiac Solutions Pty L | Organ preconditioning, arrest, protection, preservation and recovery |
| US20060034941A1 (en) | 2002-12-23 | 2006-02-16 | Global Cardiac Solutions Pty Ltd | Organ preconditioning, arrest, protection, preservation and recovery |
| CA2468664C (en) | 2003-06-03 | 2012-03-06 | Allergan, Inc. | Ketorolac tromethamine compositions for treating or preventing ocular pain |
| AU2005207037A1 (en) | 2004-01-22 | 2005-08-04 | Nitromed, Inc. | Nitrosated and/or nitrosylated compounds, compositions and methods of use |
| DK1758596T3 (da) * | 2004-05-26 | 2010-07-26 | Inotek Pharmaceuticals Corp | Purinderivater som adenosin-A1-receptoragonister og fremgangsmåder til anvendelse deraf |
| CN101010085B (zh) | 2004-05-26 | 2012-12-26 | 伊诺泰克制药公司 | 嘌呤衍生物作为腺苷a1受体激动剂及其用法 |
| CA2573682A1 (en) | 2004-07-12 | 2006-02-16 | Cv Therapeutics, Inc. | Process for the preparation of a1 adenosine receptor agonists |
| JP5688199B2 (ja) * | 2004-10-18 | 2015-03-25 | ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング | 平滑筋を弛緩させる活性成分を含むリポソーム組成物、その組成物の製造方法、及び治療剤としての用途 |
| US20090220516A1 (en) | 2005-06-22 | 2009-09-03 | Alan Laties | Neuroprotection of retinal ganglion cells |
| EA015683B1 (ru) * | 2005-11-30 | 2011-10-31 | Инотек Фармасьютикалз Корпорейшн | Производные пурина и способы их применения |
| BRPI0707446A2 (pt) | 2006-02-02 | 2011-05-03 | Allergan Inc | composições e métodos para o tratamento de doença oftálmica |
| US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
| US20070238694A1 (en) | 2006-03-23 | 2007-10-11 | Inotek Pharmaceuticals Corporation | Purine compounds and methods of use thereof |
| US8163737B2 (en) | 2006-06-13 | 2012-04-24 | Vertex Pharmaceuticals Incorporated | CGRP receptor antagonists |
| BRPI0714587A2 (pt) | 2006-07-25 | 2013-05-07 | Osmotica Corp | suluÇço oftÁlmica aquosa e uso da nesna |
| MX2009003750A (es) | 2006-10-06 | 2009-06-18 | Univ Pennsylvania | Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular. |
| NZ576524A (en) | 2006-11-10 | 2012-01-12 | Basf Se | Crystalline modification of fipronil |
| EP2099468B1 (en) | 2006-12-05 | 2018-07-11 | The Royal Institution for the Advancement of Learning/McGill University | Methods of use of trk receptor modulators |
| JP2008266143A (ja) | 2007-04-16 | 2008-11-06 | Santen Pharmaceut Co Ltd | アデノシン誘導体を有効成分として含有する緑内障治療剤 |
| EP2205071B1 (en) | 2007-10-11 | 2015-07-22 | Biogen MA Inc. | Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma |
| WO2009076580A2 (en) | 2007-12-12 | 2009-06-18 | Thomas Jefferson University | Compositions and methods for the treatment and prevention of cardiovascular diseases |
| JP2011511802A (ja) | 2008-02-07 | 2011-04-14 | ギリアード・パロ・アルト・インコーポレイテッド | Ａｂｃａ−１を上昇させる化合物およびかかる化合物の使用方法 |
| EP3693014A1 (en) | 2008-11-13 | 2020-08-12 | The General Hospital Corporation | Methods and compositions for regulating iron homeostasis by modulation bmp-6 |
| NZ596428A (en) * | 2009-05-01 | 2014-03-28 | Inotek Pharmaceuticals Corp | Method of reducing intraocular pressure in humans |
| EP2493480A4 (en) | 2009-10-26 | 2013-04-10 | Inotek Pharmaceuticals Corp | OPHTHALMIC FORMULATION AND MANUFACTURING METHOD THEREFOR |
| WO2011077435A1 (en) | 2009-12-22 | 2011-06-30 | Bar-Ilan University | Compositions and methods for reducing intraocular pressure |
| IN2012DN06592A (forum.php) | 2010-01-11 | 2015-10-23 | Inotek Pharmaceuticals Corp | |
| US20110217262A1 (en) | 2010-03-05 | 2011-09-08 | Kornfield Julia A | Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability |
| SI2555776T1 (sl) * | 2010-03-19 | 2017-05-31 | Inotek Pharmaceuticals Corporation | Kombinirani sestavki adenozin A1 agonistov in ne-selektivni blokatorji beta-adrenergičnega receptorja za zmanjšanje intraokularnega tlaka |
| RS55617B1 (sr) | 2010-03-19 | 2017-06-30 | Inotek Pharmaceuticals Corp | Kombinovane kompozicije adenozinskih a1 agonista i inhibitora ugljene anhidraze za snižavanje intraokularnog pritiska |
| WO2011119919A1 (en) | 2010-03-26 | 2011-09-29 | Inotek Pharmaceuticals Corporation | Adenosine compounds and their use thereof |
| SG184221A1 (en) * | 2010-03-26 | 2012-10-30 | Inotek Pharmaceuticals Corp | Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof |
-
2011
- 2011-01-11 IN IN6592DEN2012 patent/IN2012DN06592A/en unknown
- 2011-01-11 AU AU2011203897A patent/AU2011203897B2/en not_active Ceased
- 2011-01-11 EA EA201201011A patent/EA025415B1/ru not_active IP Right Cessation
- 2011-01-11 CA CA2784908A patent/CA2784908A1/en not_active Abandoned
- 2011-01-11 PT PT117323097T patent/PT2523669T/pt unknown
- 2011-01-11 SM SM20170017T patent/SMT201700017T1/it unknown
- 2011-01-11 MX MX2012007661A patent/MX2012007661A/es active IP Right Grant
- 2011-01-11 SG SG2012047882A patent/SG182285A1/en unknown
- 2011-01-11 JP JP2012548226A patent/JP2013516495A/ja active Pending
- 2011-01-11 ES ES11732309.7T patent/ES2613698T3/es active Active
- 2011-01-11 HU HUE11732309A patent/HUE030566T2/en unknown
- 2011-01-11 EP EP11732309.7A patent/EP2523669B1/en active Active
- 2011-01-11 LT LTEP11732309.7T patent/LT2523669T/lt unknown
- 2011-01-11 CN CN201180005821.9A patent/CN102711771B/zh not_active Expired - Fee Related
- 2011-01-11 SG SG10201502588UA patent/SG10201502588UA/en unknown
- 2011-01-11 BR BR112012017106A patent/BR112012017106A2/pt not_active IP Right Cessation
- 2011-01-11 WO PCT/US2011/020808 patent/WO2011085361A1/en not_active Ceased
- 2011-01-11 DK DK11732309.7T patent/DK2523669T3/en active
- 2011-01-11 KR KR1020127019681A patent/KR20120115344A/ko not_active Abandoned
- 2011-01-11 ME MEP-2017-11A patent/ME02608B/me unknown
- 2011-01-11 PL PL11732309T patent/PL2523669T3/pl unknown
- 2011-01-11 RS RS20170063A patent/RS55615B1/sr unknown
- 2011-01-11 SI SI201131077A patent/SI2523669T1/sl unknown
- 2011-01-11 US US13/004,380 patent/US8877732B2/en not_active Expired - Fee Related
- 2011-01-11 PH PH1/2012/501320A patent/PH12012501320A1/en unknown
- 2011-01-11 HR HRP20170007TT patent/HRP20170007T1/hr unknown
-
2012
- 2012-06-24 IL IL220604A patent/IL220604A/en not_active IP Right Cessation
- 2012-07-09 CL CL2012001912A patent/CL2012001912A1/es unknown
- 2012-08-10 CO CO12135136A patent/CO6571924A2/es not_active Application Discontinuation
-
2014
- 2014-10-17 US US14/517,509 patent/US9370530B2/en not_active Expired - Fee Related
-
2015
- 2015-12-04 JP JP2015237859A patent/JP2016040320A/ja active Pending
-
2016
- 2016-05-18 US US15/158,188 patent/US20160367586A1/en not_active Abandoned
-
2017
- 2017-01-16 SM SM201700017T patent/SMT201700017B/it unknown
- 2017-01-23 CY CY20171100093T patent/CY1118510T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02608B (me) | Kombinacija, komplet i postupak snižavanja intraokularnog pritiska | |
| CA3045733A1 (en) | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases | |
| RU2012103538A (ru) | Композиции и способы ингибирования пути jak | |
| Dams et al. | Therapeutic uses of prostaglandin F2α analogues in ocular disease and novel synthetic strategies | |
| JP2013542239A5 (forum.php) | ||
| ME02594B (me) | Kombinovane kompozicje adenozinskih a1 agonista i ne-selektivnih beta- adrenergičnih receptor blokera za snižavanje intraokularnog pritiska | |
| CN103191129A (zh) | 治疗眼睛病症的脂氧化物类化合物 | |
| NZ588938A (en) | Sustained release delivery of active agents to treat glaucoma and ocular hypertension | |
| MX2020009132A (es) | Composiciones farmaceuticas que comprenden nebivolol. | |
| IL274234B2 (en) | Compositions and methods for the treatment of eye disorders | |
| ME02593B (me) | Kombinovane kompozicije adenozinskih a1 agonista i inhibitora ugljene anhidraze za snižavanje intraokularnog pritiska | |
| JP2013528563A5 (forum.php) | ||
| CA2807081A1 (en) | Preservative free bimatoprost and timolol solutions | |
| AR062395A1 (es) | Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares | |
| JP2022530471A (ja) | 神経保護のためのカンナビノイドの組成物及び使用方法 | |
| NO20092764L (no) | Isosorbid mononitrat derivater for behandling av okular hypertensjon | |
| FI2765988T3 (fi) | Silmäkoostumus, joka sisältää bromfenaakkia, jolla on parannettu biologinen hyötyosuus | |
| WO2013184650A3 (en) | Treatment of ocular inflammatory diseases using laquinimod | |
| JP6820847B2 (ja) | プロスタグランジンと一酸化窒素供与体との組み合わせ | |
| Bagnis et al. | Antiglaucoma drugs: The role of preservative-free formulations | |
| CA2806973A1 (en) | Preservative free bimatoprost solutions | |
| JP2009500397A5 (forum.php) | ||
| JP2009500398A5 (forum.php) | ||
| ES2624446T3 (es) | Compuestos donantes de óxido nítrico a base de quinona para uso oftalmológico | |
| ATE525349T1 (de) | Pharmazeutische prostaglandinzusammensetzungen |